News
CMPS
10.23
-1.63%
-0.17
Psychedelic Stock Gainers And Losers From March 28, 2023
Benzinga · 15h ago
Psychedelic Stock Gainers And Losers From March 27, 2023
Benzinga · 1d ago
10 Short Squeeze Candidates: Unicycle Therapeutics, Compass Pathways, Virgin Orbit Among Those To Watch
Benzinga · 1d ago
GH Research, Cybin Among Top Psychedelic Movers Of Today
Benzinga · 4d ago
Atai Life Sciences Hopes Hercules Can Help 'Sustain' Operations Until 2026
Benzinga · 4d ago
GH Research, Compass Pathways Among Top Psychedelic Movers Of Today
Benzinga · 5d ago
Psychedelic Stock Gainers And Losers From March 22, 2023
Benzinga · 6d ago
Psychedelic Stock Gainers And Losers From March 21, 2023
Benzinga · 03/21 21:30
Psychedelic Stock Gainers And Losers From March 20, 2023
Benzinga · 03/20 21:30
Psychedelic Stock Gainers And Losers From March 17, 2023
Benzinga · 03/17 21:30
Seelos Therapeutics, Compass Pathways Among Top Psychedelic Movers Of Today
Benzinga · 03/16 21:30
Seelos Therapeutics, Cybin Among Top Psychedelic Movers Of Today
Benzinga · 03/15 21:30
Seelos Therapeutics, ATAI Life Sciences Among Top Psychedelic Movers Of Today
Benzinga · 03/14 21:30
ATAI Life Sciences, Compass Pathways Among Top Psychedelic Movers Of Today
Benzinga · 03/13 21:30
Seelos Therapeutics, GH Research Among Top Psychedelic Movers Of Today
Benzinga · 03/10 21:30
Where Compass Pathways Stands With Analysts
Benzinga · 03/10 12:01
Analysts Offer Insights on Healthcare Companies: aTyr Pharma (LIFE), COMPASS Pathways (CMPS) and Olema Pharmaceuticals (OLMA)
TipRanks · 03/10 11:20
Psychedelic Stock Gainers And Losers From March 9, 2023
Benzinga · 03/09 21:30
'Oklahoma House Approves Psilocybin Bill Protecting Patients From Prosecution And Promoting Research' - Marijuana Moment
Benzinga · 03/09 18:10
Numinus Wellness, Seelos Therapeutics Among Top Psychedelic Movers Of Today
Benzinga · 03/08 21:30
More
Webull provides a variety of real-time CMPS stock news. You can receive the latest news about Compass Pathways Plc through multiple platforms. This information may help you make smarter investment decisions.
About CMPS
COMPASS Pathways plc is a United Kingdom-based mental healthcare company. The Company is developing psilocybin therapy through late-stage clinical trials in Europe and North America for patients with treatment-resistant depression (TRD). The Company has developed COMP360, which is a psilocybin formulation that includes its pharmaceutical-grade polymorphic crystalline psilocybin. The Company's COMP360 has completed a Phase IIb clinical trial of psilocybin therapy for TRD, in 22 sites across Europe and North America. Its randomized controlled Phase IIb study of psilocybin therapy in treatment-resistant depression is the psilocybin therapy clinical trial, with approximately 233 patients across 22 sites in 10 European and North American countries. This trial assessed the safety and efficacy of COMP360 psilocybin therapy in three doses: 1mg, 10mg, 25mg. The Company is also running a Phase II clinical trial of COMP360 psilocybin therapy for post-traumatic stress disorder (PTSD).